Trials / Completed
CompletedNCT00073125
Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and efficacy of ABT-510 in subjects with advanced renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-510/Thrombospondin-1 mimetic |
Timeline
- Start date
- 2003-05-01
- First posted
- 2003-11-18
- Last updated
- 2007-08-15
Locations
18 sites across 2 countries: United States, Netherlands
Source: ClinicalTrials.gov record NCT00073125. Inclusion in this directory is not an endorsement.